Immunomodulatory strategies for celiac disease.
Celiac disease (CD) is the most common food-sensitive enteropathy in humans and is caused by the lack of immune tolerance (oral tolerance) to gluten. The identification of gluten-specific T cells in the lamina propria of celiacs and the strong association with HLA-DQ2 and -DQ8 genes support a central role of CD4(+) T cells in CD pathogenesis. Studies focused on the modulation of autoimmunity in different experimental models highlighted possible immune therapeutic protocols useful also for the management of CD. On the basis of these observations, a series of strategies have been designed: some of them are based on the identification of immunogenic epitopes and their suppression via enzymatic treatment or by using peptide analogues; others rely on the delivery of unmodified antigen through the nasal route or coadministered with downregulatory cytokines. studies are generally early stage but encouraging in paving a way for an alternative treatment for celiac disease.
Rossi
Mauro
M
Istituto di Scienze dell'Alimentazione, CNR, Avellino, Italy. mrossi@isa.cnr.it
Maurano
Francesco
F
Luongo
Diomira
D
D000818:Animals; D002446:Celiac Disease / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D041981:Gastrointestinal Tract / Q000276:immunology; D005903:Gliadin / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D018928:Immunity, Mucosal / Q000276:immunology; D007165:Immunosuppression Therapy / Q000379:methods; D007167:Immunotherapy / Q000379:methods*; D016753:Interleukin-10 / Q000627:therapeutic use; D018448:Models, Immunological; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D010446:Peptide Fragments; D016753:Interleukin-10; D005903:Gliadin